

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : A61K 9/16, 9/72, B01J 2/00	A1	(11) International Publication Number: WO 95/09616 (43) International Publication Date: 13 April 1995 (13.04.95)
<p>(21) International Application Number: PCT/SE94/00897</p> <p>(22) International Filing Date: 29 September 1994 (29.09.94)</p> <p>(30) Priority Data: 9303215-9 1 October 1993 (01.10.93) SE 9304270-3 22 December 1993 (22.12.93) SE</p> <p>(71) Applicant (for all designated States except US): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): TROFAST, Eva [SE/SE]; Vapenkroken 34, S-226 47 Lund (SE). OLSSON, Magnus [SE/SE]; Tomgapsgatan 5, S-223 50 Lund (SE). AHL- NECK, Claes [SE/SE]; Ö:a Förstadsgatan 23 A, S-211 31 Malmö (SE).</p> <p>(74) Agent: SIVBORG, Susanne, Ås; Astra AB, Patent Dept., S-151 85 Södertälje (SE).</p>		<p>(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).</p> <p>Published With international search report.</p>
<p>(54) Title: PROCESS II</p> <p>(57) Abstract</p> <p>According to the invention there is provided a method of treatment of a finely divided powdered medicament having a particle size smaller than 10 <math>\mu\text{m}</math> and poor flowing properties to form, in a controlled manner, agglomerates or pellets which are free flowing and which are capable of breaking down to provide the finely divided medicament, comprising the steps of agglomerating the powdered medicament having a particle size being smaller than 10 <math>\mu\text{m}</math> by feeding the material to a sieve, causing the finely divided powdered medicament to pass through the apertures of the sieve thereby obtaining agglomerates, spheronizing the resulting agglomerates in order to provide agglomerates which are more spherical, more dense and more compact than the agglomerates resulting from the agglomeration process in the sieve, and sizing the agglomerates to obtain a uniform size of the final product. According to the invention there is also provided an apparatus for carrying out the method.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## Process II

Background of invention

- 5 The invention relates to a method and an apparatus for making a powder consisting of particles having a particle size smaller than 10  $\mu\text{m}$  free-flowing by forcing the particles to create agglomerates.

10 Powders consisting of very small particles are commonly used in the inhalation therapy where the size of the particles are of utmost importance. The diameter of particles which are to be inhaled must be less than 10  $\mu\text{m}$  to ensure the adequate penetration of the particles into the bronchial area of the lungs.

- 15 Most finely divided powders, such as micronized powders, are light, dusty and fluffy and they often create problems during handling, processing and storing. For particles having a diameter less than 10  $\mu\text{m}$  the van der Waals forces are generally greater than the force of gravity and consequently the material is cohesive. The particles tend to adhere to each other forming  
20 non-defined agglomerates. Such powders have very poor free-flowing properties which often make handling and precise metering problematic.

- One possible method of making these powders free-flowing or at least improve their flowing properties is to force, in a controlled manner, the  
25 primary particles to form larger particles, agglomerates. Non-defined agglomerates are formed at random when this finely divided material is handled, for instance during storage, conveying, sieving, sifting, mixing or grinding.

It is common knowledge that spherical agglomerates flow freely, packs easily and uniformly, have an ideal form for coatings and are therefore commonly used in drug formulations.

- 5     The flow of very cohesive powders can be improved by vibration-induced agglomeration. Depending on the type of powder, liquid (often water) or solid binders are added during the agglomeration, but it is also possible to agglomerate without binders.
- 10    The method of agglomeration is applicable in principle to all materials, including mixtures of various powders. Any powder, provided it contains a sufficient amount of fine particles having a size smaller than 10  $\mu\text{m}$ , can be granulated or pelletized without a binder by systematic agitation or rolling of the particulate material.
- 15    The agglomerated powders consist of relatively large, more dense and compact spheres which exhibit the normal flow properties, but at the same time the spheres should have sufficient low internal coherence to break up into small primary particles of medicament of a therapeutically effective
- 20    size during inhalation in an inhalation device.

- The inhaled route of administration enables the dose to be delivered directly to the airways. By this type of administration it is possible to give a small dose and thereby minimizing unwanted side effects, which for
- 25    example could occur if the substance is deposited in another part of the body, e.g. the gastrointestinal tract or the oro-laryngeal tract.

Prior art

- Methods of controlled agglomeration are known in the prior art. For example, Claussen and Petzow (Journal of Materials Technology, vol 4(3), 148-156 (1973)) have described a dry agglomeration method where no
- 5 binders are intentionally added for preparation of spheres in the size range 0.1 - 3 mm by tumbling in a cylinder tilted at an angle to the horizontal axis of rotation. According to the authors a dry agglomeration process for small particles requires nuclei in order to start, but almost all powders consist of natural agglomerates that function as nuclei. They also conclude that
- 10 agglomerates from common used devices such as a rotating drum or a granulating pan form a wide size distribution of the agglomerates that makes frequent sieving necessary. The product formed often exhibit bad sphericity and low density.
- 15 US-A-5 143 126 describes a vibratory conveyor for forming flowable agglomerates from previously poorly flowable fine-grained powder by using a method wherein the poorly flowable powder is subjected to a mechanical vibration step prior to transport and metering.
- 20 GB-A-1 569 611 describes a process for agglomeration of a drug into soft pellets. In this process moist is used as a binder to provide a doe which by extrusion is pressed through a sieve to create agglomerates.
- 25 GB-A-2 187 952 describes a method in which crystalline ibuprofen is compacted by kneading as it is conveyed by conveying screws through an extruder. The resulting agglomerates can also be passed through an extruder plate affixed to an end of the extruder.
- 30 EP-A-0 490 649 a laboratory process for obtaining soft pellets is described. In this process a sieve was used having an aperture size between 210 to 500

microns. A palett knife was used to extrude the powder through the sieve. The extrudate formed was placed in a glass jar which was placed on a set of rollers in order to further treat the extrudate.

5    The invention

It is an object of the present invention to provide a method of controlled agglomeration of finely divided powdered medicament having a primary particle size smaller than 10  $\mu\text{m}$ , preferably smaller than 5  $\mu\text{m}$ , for example  
10   micronized powders, in which no binders are needed and in which the resulting agglomerates are of a uniform size having a structure which provides sufficient flowability for the transport and metering of such powders and which nevertheless have sufficient low internal coherence to break up, within an inhalation device, such as a dry powder inhalator, into  
15   particles of medicament having a therapeutically effective size, e.g. having a particle size smaller than 10  $\mu\text{m}$ .

The method according to the invention provides a process for facilitating the technical handling and significantly increase the medical value of the  
20   substance. It has been found that this method produces agglomerates having excellent handling properties, which have sufficient strength to withstand packaging and storage, but which are sufficient soft so that they will break down into primary particles when they are expelled from the inhalator during inhalation therapy.

25

According to the invention there is provided a method for the manufacture of agglomerates, which comprises subjecting the finely divided particles of the medicament, which could be in admixture with any other ingredient desired to be incorporated into the agglomerates, to mechanical unit  
30   operations under certain conditions. More specifically there is provided a

- method of treatment of a finely divided powdered medicament having a particle size smaller than 10  $\mu\text{m}$  and poor flowing properties to form, in a controlled manner, agglomerates or pellets which are free flowing and which are capable of breaking down to provide the finely divided medicament, comprising the steps of:
- a) agglomeration of the powdered medicament having a particle size being smaller than 10  $\mu\text{m}$  by feeding the material to a sieve, causing the finely divided powdered medicament to pass through the apertures of the sieve thereby obtaining agglomerates,
  - b) spheronizing the resulting agglomerates in order to provide agglomerates which are more spherical, more dense and more compact than the agglomerates obtained from the agglomeration process in the sieve, and
  - c) sizing the agglomerates to obtain an uniform size of the final product.
- According to the invention there is also provided an apparatus for performing the method of treatment of a finely divided powdered medicament having a particle size smaller than 10  $\mu\text{m}$  and poor flowing properties to form, in a controlled manner, agglomerates or pellets which are free flowing and which are capable of breaking down to provide the finely divided medicament, comprising a sieve having apertures through which the finely divided powder is mechanically caused to pass to obtain agglomerates, a spheronizing device and a sizing device for sizing the agglomerates to obtain a uniform size of the final product.
- Further preferred steps of the method are clear from the appended dependent claims 2 - 14 and preferred embodiments of the apparatus are clear from the appended dependent claims 15 - 25.
- There is also provided a use of the apparatus to carry out the method according to the invention.

It is also an object of the invention to provide a use of the agglomerates manufactured in accordance with the method in a breath actuated dry powder inhaler, such as Turbuhaler®.

5    Brief description of the drawings

The method according to the present invention will now be described by way of example with reference to the appended drawings, wherein:

- 10    Fig. 1 shows a schematic view of a first embodiment of the apparatus and process according to the invention,

Fig. 2 is a sectional view along line A - A in fig. 1,

- 15    Fig. 3 shows a schematic view of an alternative of the apparatus and process shown in fig. 1,

Fig. 4 shows a schematic view of a second embodiment of the apparatus and process according to the invention,

- 20    Fig. 5 shows a schematic view of an alternative of the apparatus and process shown in fig. 4,

- Fig. 6 shows a schematic view of the apparatus according to the invention  
25    having a third embodiment of the agglomerating sieve,

Fig. 7 is a diagram showing size distribution of spheres as a function of different sizes of the apertures in the used sieve.



Detailed description of the drawings

According to the invention the finely divided powdered medicament is supplied to a sieve 2, 102, 202 through which apertures the powder is forced. Mechanical devices are used to press the powder through the apertures. During this treatment small, soft agglomerates or pellets are formed which are capable of breaking down to provide the finely divided medicament and which could be spheronized to obtain a more spherical, dense and stable form. The agglomerates resulting from the spheronizing process are harder than the agglomerates resulting from the agglomeration process but are still capable of breaking down to provide the finely divided medicament which, as already mentioned above, is of utmost importance when the agglomerates are to be used in the inhalation therapy.

A first embodiment of the apparatus for carrying out the method according to the invention can be seen in fig. 1. The sieve 2 which is used for the agglomeration is hereby formed as a trough 6 having a substantially U-shaped form. The walls of the U-shaped trough are made of a net 8 of any rigid material such as metal, plastic or other suitable material.

The size of the resulting agglomerates is depending on the size of the apertures in the net 8. To obtain agglomerates which have a size and form which make them suitable for the following spheronization treatment, which is described in more details below, the size of the apertures should be between 0.2 - 2.0 mm, preferably between 0.3 - 1.0 mm.

Inside the U-shaped trough an oscillating and/or rotating device 10 is provided. This oscillating device 10 is preferably provided with at least one arm 12 mounted on a shaft 14 which is arranged along the longitudinal axis of the U-shaped trough 6 as shown in fig. 1 and 2. In the preferred

embodiment the oscillating device 10 is provided with four arms 12 mounted perpendicular to each other. In the end of each arm a plate 16 is mounted in a right angle to the arm 12, see fig. 2. These plates will, due to the oscillating movement of the oscillating device 10, when oscillating  
5 and/or rotating, force the finely divided powder supplied to the U-shaped trough 6 through the apertures of the net 8 thereby forming the agglomerates.

The shaft 14 of the oscillating device 10 is mounted to a motor 4 or similar  
10 which is provided to produce and transmit the oscillating and/or rotating movement to the device.

The agglomerates obtained from the sieve after the agglomeration process have different sizes and are comparatively soft, they need to be further  
15 treated to obtain the desired characteristics. The agglomerates are therefore collected in a spheronizing device, preferably a rotating container, such as a pan or drum 18 which preferably is provided with one or more scrapers 20 (only shown schematically in the drawings). The container 18 is tilted and is rotating. The rotating movement of the container 18 will make the  
20 agglomerates rotate and tumble due to the tilting of the container. The scrapers will give the agglomerates a further rotation and shaping thereby improving the spheronization. During the rotation the agglomerates will obtain a stronger, more dense, compact and uniform form and a smoother outer surface. These improvements in form, hardness and density achieved  
25 in the rotating container 18 will further improve the flowability and the resistance against breaking during handling and storage. The speed of the container determines the characteristics of the agglomerates after this spheronization. Tests have shown that the optimal periphery speed of the  
30 spheronization time is preferably between 1 - 20 min. Tests have shown that

after 3 - 10 min the agglomerates often have obtained the required optimal size, capability of breaking down to provide the finely divided medicament and density for their future use.

- 5 Tests have shown that the most optimum tilting angle of the container 18 is between 10°- 80° from the vertical, preferably between 30°- 60° as an angle chosen herebetween gives the best densifying and growing effect to the agglomerates.
- 10 The granulating container is made of a material which is inert and do not contaminate the powder, such as for example metal, plastic or any other suitable material. In order to avoid electrostatic forces to build up during the spheronization process the container could be grounded.
- 15 After the spheronization in the tilted container 18 the agglomerates are supplied to a sizing device, preferably a sieve 22 having an aperture size which is between 0.2 - 2.0 mm, preferably between 0.3 - 1.0 mm. This final sieving is used in order to obtain a uniform size of the agglomerates. The requirements for the use of this operation is strongly depending on the type
- 20 of inhalation device to be used.

The requirements of uniform size and proper density is higher if the agglomerates are to be used in a dry powder inhaler. During inhalation it is of utmost importance that agglomerates are broken up into a high amount

25 of primary particles having a particle size smaller than 10  $\mu\text{m}$ .

To utilize the process in the most efficient and economic manner and to minimize the amount of agglomerates which are too big and therefore have to be recycled into the process the method could comprise further steps of

30 sieving and spheronization. The final agglomerates will also be more

uniform which will improve the break down of the agglomerates into primary particles during inhalation. A further step of sieving is incorporated hereby into the process after the spheronization and a second spheronization is incorporated after this extra sieving. An apparatus according to this embodiment of the invention is shown in fig 3. The finely divided powdered medicament is agglomerated in the substantially U-shaped trough 6' and the resulting agglomerates are supplied to the granulating container 18'. After the spheronization the agglomerates are supplied to a sieve 24' to obtain a more uniform size. After this sieving the agglomerates are spheronized a second time in a second granulating container 26'. This second granulating container 26' is of the same type as the first container 18' and the periphery speed and the spheronization time as defined above for the first step of spheronization. After this second spheronization the agglomerates are sifted through the final sieve 22' to obtain a uniform size of the final product. The sifting is necessary as in some case the agglomerates might grow too much during the spheronization and therefore the final product could contain agglomerates having a size being bigger than the required size, e.g. 0.2 - 2 mm, preferably 0.3 - 1 mm.

20

In fig. 4 a second embodiment of an apparatus for carrying out the method according to the invention is shown. In this embodiment the finely divided powdered medicament is supplied to a plain, substantially horizontal sieve 106 which is provided with a mechanical device 110 which forces the finely divided powder through the apertures of the net 108 in the sieve 106. During this extrusion of the powder through the apertures small, soft agglomerates or pellets will be formed which have the required characteristics for the following densifying treatment in the granulating container. Also in this embodiment the last step of the process includes a sieving of the agglomerates to obtain uniform size of the final product.

30

The mechanical device which forces the powder through the apertures of the sieve could preferably be formed as a scraper 112 which describes a reciprocating movement over the net 108 of the sieve 106 and which during this movement forces the finely divided powdered medicament down  
5 through the apertures of the sieve 106.

The size of the apertures of the sieve is related to the required size of the agglomerates. As already mentioned above the size is between 0.2 - 2.0 mm, preferably between 0.3 - 1.0 mm. The preferred size of the apertures will  
10 give the agglomerates a size which makes them suitable for the following spheronization.

Also in this embodiment of the invention the agglomerates resulting from the agglomeration process in the plain, substantially horizontal sieve 106  
15 need to be further treated to obtain the desired characteristics. The agglomerates are therefore collected in a rotating container 118 having one or more scrapers 120. The container is of the same type as described in relation to the first embodiment of the invention as well as the speed of the container and the spheronization time and angle.

20

The process is thereafter finished by a final sifting in a sieve 122 as described in relation to the first embodiment.

If required the process according to this second embodiment can also be  
25 completed with the further steps of sieving and spheronization as described above in relation to the first embodiment of the method according to the invention.

This alternative of the second embodiment is shown in fig. 5 where a  
30 second sieve 124 and a second granulating container 126 is incorporated into

the apparatus after the first granulating container 118' and before the final sifting in the sieve 122'.

In fig. 6 a third embodiment of the agglomerating sieve is shown. The net  
5 208 of the sieve is formed as a truncated cone and is provided with a  
scraper device 212. The scraper device could have any form but is  
preferably formed a horisontal element mounted on a shaft. At least two  
arms extends outwardly form the horisontal element in the angle of the net  
208, e.g. the truncated cone. The shaft is connected to a motor 204 which  
10 gives the scraper device 212 a rotating movement. During the  
agglomeration process the rotation of the scrapers will force the finely  
divided particles of the powder to pass through the apertures in the net 208  
thereby forming well defined agglomerates having the required  
characteristics.

15 After agglomeration the agglomerates are treated as described in relation to  
embodiment one and two of the present invention.

The agglomeration process according to the invention will now be  
20 described by experiments which are intended to illustrate but not limit the  
scope of the invention as described in the appended claims.

The agglomerates obtained from the process according to the invention are  
to be used in a dry-powder inhalator, preferably in a dry-powder breath-  
25 actuated inhalator. The hardness of the agglomerates are therefore of  
utmost importancy. The required hardness of agglomerates which are  
capable of breaking down into primary particles during inhalation has been  
measured by a MHT-4 Microhardness tester, (A.Paar, Austria) and has been  
found to vary between 0.5 to 20 mN for agglomerates having good  
30 deagglomeration properties and which break down into the required

primary particles in an inhalator during inhalation. With values above 20 mN the deagglomeration of the agglomerates will be less and above 100 mN very little deagglomeration of the agglomerates will occur.

5

### Example 1

Properties of agglomerates of three different powders have been determined and is to be seen in the table below. The powder consisted of finely divided particles which was passed through the steps of the method according to  
10 the invention:

	SUBSTANCE	MASS MEDIUM	SURFACE AREA	BULK DENSITY
		DIAMETER ( $\mu\text{m}$ )	( $\text{m}^2/\text{g}$ )	( $\text{g}/\text{ml}$ )
	Terbutaline	1.7	9	0.25
15	Budesonide	2.0	6	0.24
	Lactose	3.0	6	0.32

Typically the bulk density for agglomerated powders consisting of finely divided particles can be determined to vary between 0.2 mg to 0.4 g/ml for  
20 particles having a particle size of less than 10  $\mu\text{m}$ . The surface area varies between substances but there is no difference between micronised and micronised and agglomerated (and spheronised) powder. The area is between 2 - 20  $\text{m}^2/\text{g}$ , preferably 3 - 12  $\text{m}^2/\text{g}$ .

25

### Example 2

Micronized (mass medium diameter (MMD)) 3.2  $\mu\text{m}$  lactose was slowly added on the oscillating device consisting of a U-shaped sieve net mounted on an Erweka AR 400. By the action of the bars of the oscillating device the  
30 lactose was pushed through the sieve net. The mesh size of the sieve net

used was in one experiment 0.63 mm and in another experiment 1.0 mm. The oscillating frequency was in each case 90 turns/min. The agglomerates formed were collected and added to a stainless granulator (Eirisch type, 240 mm diameter), fixed at an angle of about 45° and equipped with a scraper, for growth of the spheres to occur. Tumbling of the agglomerates was performed at 50 rpm for 8 minutes. The spheres were collected and analyzed for size distribution in a Retsch sieve with a mesh size up to 2 mm. For comparison micronized lactose was spheronized without prior treatment in the oscillating sieve. The result is shown in the diagram in Fig. 7.

### Example 3

Agglomeration starts with particle-particle contact and adhesion (nucleation). These bodies act as nuclei for further growth of the agglomerates. The agglomeration step according to the present invention will create small spheres of relatively uniform size in the tumbling process, while direct tumbling of the fine cohesive powder will give large spheres with a wide size distribution. The difference in sphere size is thus due to different growth occurring during the tumbling. Since sieving through an oscillating device with a small sieve mesh produced nuclei of controlled size, less unagglomerated fine particles were left to increase the size of the agglomerates. The existence of a lot of non-agglomerated fine particles will give an uncontrolled sphere growth during tumbling and to larger variations in size distributions and a larger average sphere diameter and average sphere volume. This is shown in the diagram below, where the average sphere diameter (msd) and weight average sphere volume (msv) for spheres obtained after eight minutes of growth in a stainless granulator has been calculated as well as the relative standard deviation (RSD).



	<u>MSD</u>	<u>RSD</u>	<u>MSV</u>	<u>RSD</u>
Nucleation step	mm	%	mm <sup>3</sup>	%
Sieve 0.63	0.813	1.4	0.335	3
Sieve 1.0	0.851	7.4	0.433	9.8
5 No sieve	3.18	13.3	73.2	92.1

The experiments clearly show the narrow distribution of the sphere sizes obtained in a U-shaped sieve compared with a direct spheronization procedure of the primary finely divided powder. A more uniform size of the spheres with the smaller size aperture, preferably a size of 0.3 to 1.2 is therefore recommended. Large agglomerates/spheres may eventually break up and thereby giving a wide range of agglomerate/sphere size distribution, which gives less accurate doses.

As a consequence the described process according to the present invention gives an agglomerated powder with acceptable batch to batch variations of the final product. Small variations is of utmost importance for accuracy of a dose from an inhalation device.

#### Possible modifications

The method according to the invention could of course be modified within the scope of the appended claims as well as the apparatus.

Thus the shape of the sieve or the extrusion device where the controlled agglomeration takes place could be varied as well as the size of the apertures. This size must be chosen in regard to the characteristics of the finely divided powdered medicament to be agglomerated. The apertures of the sieve could for example have different shape, e.g. being round or having any other preferred shape.

The oscillating and/or rotating device or mechanical scraper device which forces the powder through the apertures of the net could have any suitable form. For example in the first embodiment with the U-formed trough the device could be formed as a tape being provided with wings arranged on the tape perpendicular to the net. Other forms are also possible within the scope of the claims.

It is also possible to modify the size, shape, speed and tilting angle of the granulating container thereby changing the size of the final agglomerates.

10

The spheronization could also be done in a so called marumerizer which is a commercially available apparatus for spheronization or granulation. The spheronization could also be done in any other suitable way using a rotation symmetrical receptacle or container, which could be rotated, such as any container being cylindrical or barrel formed.

15

Claims

1. Method of treatment of a finely divided powdered medicament having a particle size smaller than 10  $\mu\text{m}$  and poor flowing properties to form, in a controlled manner, agglomerates or pellets which are free flowing and which are capable of breaking down to provided the finely divided medicament, comprising the steps of
- 5 a) agglomerating the powdered medicament having a particle size being smaller than 10 $\mu\text{m}$  by feeding the material to a sieve, causing the finely divided powdered medicament to pass through the appertures of the sieve thereby obtaining agglomerates,
- 10 b) spheronizing the resulting agglomerates in order to provide agglomerates which are more spherical, more dense and more compact than the agglomerates obtained from the agglomeration process in the sieve, and
- 15 c) sizing the agglomerates to obtain an uniform size of the final product.
2. Method according to claim 1, characterised in that a tilted granulating container, preferably with one or more scrapers, is used to spheronize the agglomerates resulting from the agglomeration.
- 20 the agglomeration.
3. Method according to claim 1 or 2, characterised in that a sieve is used for the sizing of the resulting agglomerates.
- 25
4. Method according to any of claim 1, characterised in that the particle size of the finely divided powdered medicament is smaller than 10 $\mu\text{m}$  and in that the size of the agglomerates after the agglomeration process is less than or equal to 2 mm.
- 30

5. Method according to claim 1,  
characterised in that the finely divided powdered medicament is  
mechanically forced through the apertures of a sieve in the form of a  
substantially U-shaped trough.

5

6. Method according to claim 5,  
characterised in that the apertures of the sieve in the form of a U-  
shaped trough have a size between 0.2 - 2.0 mm, preferably between 0.3 -  
1.0 mm.

10

7. Method according to claim 5 or 6,  
characterised in that the finely divided powdered medicament is  
mechanically forced through the apertures of the sieve having the form of a  
U-shaped trough using a mechanical rotor device thereby obtaining  
agglomerates.

15

8. Method according to claim 1,  
characterised in that the powder is mechanically forced through  
the apertures of a plane sieve thereby obtaining agglomerates.

20

9. Method according to claim 8,  
characterised in that the plane sieve is substantially horizontal.

10. Method according to claim 8 or 9,

25 characterised in that the apertures of the plane sieve have a size  
between 0.2 - 2.0 mm, preferably between 0.3 - 1.0 mm.

11. Method according to claim 9 or 10,

30 characterised in that the finely divided powdered medicament is  
mechanically forced through the apertures of the substantially horizontal

sieve using a mechanical scraper device describing a reciprocating movement.

12. Method according to one or more of claims 1 to 11,  
5 c h a r a c t e r i s e d in that the method comprises further steps of sizing and spheronizing after the initial steps of agglomeration and spheronization.

13. Method according to claim 10,  
10 c h a r a c t e r i s e d in that for the further sizing a further sieve is used and for the further spheronizing a further granulating container, preferably with one or more scrapers, is used.

14. Method according to claim 12,  
15 c h a r a c t e r i s e d in that the apertures of the further sieve has a size between 0.2 - 2.0 mm, preferably 0.3 - 1.0 mm.

15. Method according to any of the preceeding claims,  
c h a r a c t e r i s e d in that the periphery speed of the granulating  
20 container preferably is 0.5 - 1.0 m/s.

16. Apparatus for forming a powdered medicament having a particle size smaller than 10  $\mu\text{m}$  and poor flowing properties into agglomerates or pellets which are free flowing and which are capable of breaking down to  
25 provide the finely divided medicament, comprising a sieve (2, 2', 102, 102', 202) having apertures through which the finely divided powdered medicament is mechanically caused to pass to obtain agglomerates, a spheronizing device for spheronizing the resulting agglomerates and a sizing device for sizing the agglomerates to obtain a uniform size of the  
30 final product.

17. Apparatus according to claim 16,  
c h a r a c t e r i s e d in that the spheronizing device is a tilted granulating  
container (18, 18', 118, 118'), preferably with one or more scrapers (20,120).
- 5 18. Apparatus according to claim 16 or 17,  
c h a r a c t e r i s e d in that the sizing device is a sieve (22, 22', 122, 122').
19. Apparatus according to any of claims 16 to 18,  
c h a r a c t e r i s e d in that the sieving device used to obtain  
10 agglomerates is a sieve in the form of a U-shaped trough (6, 6').
20. Apparatus according to claim 19,  
c h a r a c t e r i s e d in that the U-shaped trough (6, 6') is provided with  
a oscillating and/or rotating device (10) mounted inside the U-shaped  
15 trough.
21. Apparatus according to claim 20,  
c h a r a c t e r i s e d in that the oscillating and/or rotating device (10)  
comprises a shaft (14) provided along the longitudinal axis of the U-shaped  
20 trough (6, 6') and having at least one arm (12) extending perpendicular to  
the shaft (14), the arm being provided with a plate-like extrusion (16)  
arranged perpendicular to the arm (12) and in contact with the surface of  
the net.
- 25 22. Apparatus according to claim 16,  
c h a r a c t e r i s e d in that the sieving device is a plane sieve (106, 106')  
which is provided with a mechanical scraper device (110) describing a  
reciprocal movement.

23. Apparatus according to claim 22,  
characterised in that the plane sieve (106,106') is substantially  
horizontal.
- 5 24. Apparatus according to claim 22,  
characterised in that the mechanical scraper device (110) is a plate  
(112) arranged vertically and perpendicular to the horizontal plane of the  
sieve and in contact with the surface of the net.
- 10 25. Apparatus according to any of claims 19 or 22,  
characterised in that it comprises a further sieve (24, 124) for  
sieving the agglomerates and a further tilted granulating container (26, 126),  
preferably with one or more scrapers.
- 15 26. Apparatus according to claims 19 and 25 or 22 and 25,  
characterised in that the apertures of the sieves have a size  
between 0.2 - 2.0 mm, preferably between 0.3 - 1.0 mm.
- 20 27. Apparatus according to one or more of claims 16 to 26,  
characterised in that the periphery speed of the granulating  
container preferably is 0.5 - 1.0 m/s.
- 25 28. Apparatus according to claim 27,  
characterised in that the spheronization time preferably is 2 - 20  
min.
29. Use of an apparatus according to any of claims 16 to 28 to carry out a  
method according to any of claims 1 to 14.

30. Agglomerates manufactured in accordance with a method as described in claims 1 to 14 by using an apparatus as described in claims 16 to 28 for use in a breath-actuated dry powder inhaler.
- 5 31. Agglomerates according to claim 30, wherein the breath-actuated dry powder inhaler is Turbuhaler®.



1/3




FIG. 1




FIG. 2




FIG. 3







FIG. 4




FIG. 5






FIG. 6

3/3

Fig. 7

## Sphere Distribution



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 94/00897

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
IPC6: A61K 9/16, A61K 9/72, B01J 2/00 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols)		
IPC6: A61K, B01J, C08J		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
WPI, WPIL, CLAIMS, CHEMICAL ABSTRACTS		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 4161516 (JOHN H. BELL), 17 July 1979 (17.07.79), column 2, line 5 - column 3, line 54; column 7, line 22 - column 9, line 65 --	1-31
X	EP, A2, 0291201 (THE BRITISH PETROLEUM COMPANY P.L.C.), 17 November 1988 (17.11.88)	1-4
A	--	5-31
A	US, A, 5143126 (BEATE BOESCH ET AL), 1 Sept 1992 (01.09.92) --	1-31
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
12 January 1995		17 -01- 1995
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer  Anneli Jönsson Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 94/00897

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GB, A, 2187952 (THE BOOTS COMPANY PLC), 23 Sept 1987 (23.09.87)  --	1-31
A	EP, A1, 0072046 (FISONS PLC), 16 February 1983 (16.02.83)  -- -----	1-31

# INTERNATIONAL SEARCH REPORT

Information on patent family members

26/11/94

International application No.

PCT/SE 94/00897

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A- 4161516	17/07/79	AU-B- 506878	24/01/80
		AU-A- 2158977	03/08/78
		CA-A- 1116516	19/01/82
		CA-A- 1144862	19/04/83
		CH-A- 621060	15/01/81
		DE-A- 2702504	28/07/77
		FR-A,B- 2361104	10/03/78
		GB-A- 1569611	18/06/80
		JP-B- 1042950	18/09/89
		JP-C- 1423729	15/02/88
		JP-C- 1565333	25/06/90
		JP-A- 52094413	09/08/77
		JP-B- 62028124	18/06/87
		JP-A- 62246571	27/10/87
		LU-A- 76618	12/08/77
		SE-B,C- 442950	10/02/86
		SE-A- 7700665	24/07/77
EP-A2- 0291201	17/11/88	AU-B- 604882	03/01/91
		AU-A- 1560988	10/11/88
		JP-A- 63296836	02/12/88
		US-A- 4894189	16/01/90
US-A- 5143126	01/09/92	DE-D- 59100388	00/00/00
		EP-A,B- 0441740	14/08/91
		SE-T3- 0441740	
		ES-T- 2044710	01/01/94
GB-A- 2187952	23/09/87	AU-A- 7017787	24/09/87
		EP-A,B- 0241126	14/10/87
		JP-A- 62230723	09/10/87
		ZA-A- 8701836	02/09/87
EP-A1- 0072046	16/02/83	SE-T3- 0072046	
		AU-B- 540826	06/12/84
		AU-A- 8635582	10/02/83
		BE-A- 893912	24/01/83
		CA-A- 1187415	21/05/85
		CH-A,B- 657273	29/08/86
		FR-A- 2510405	04/02/83
		GB-A,B- 2105189	23/03/83
		JP-B- 4068285	02/11/92
		JP-A- 58059914	09/04/83
		LU-A- 84291	07/02/83
		US-A- 4590206	20/05/86
		US-A- 5260306	09/11/93